Achaogen Inc (NASDAQ:AKAO) hit a new 52-week low on Monday . The company traded as low as $0.16 and last traded at $0.17, with a volume of 655295 shares trading hands. The stock had previously closed at $0.50.

A number of brokerages have weighed in on AKAO. ValuEngine cut shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Monday, December 17th. Mizuho reiterated a “hold” rating and set a $3.00 price target on shares of Achaogen in a research report on Friday, February 15th. HC Wainwright reiterated a “hold” rating and set a $2.00 price target on shares of Achaogen in a research report on Thursday, February 21st. Zacks Investment Research upgraded shares of Achaogen from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research report on Tuesday, February 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Achaogen in a research report on Friday, March 29th. Two analysts have rated the stock with a sell rating and eleven have given a hold rating to the stock. The stock has an average rating of “Hold” and an average target price of $8.12.

The stock has a market cap of $31.62 million, a price-to-earnings ratio of -0.04 and a beta of 0.78. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.77 and a current ratio of 0.78.

In related news, major shareholder Robert W. Duggan sold 520,102 shares of Achaogen stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.63, for a total value of $327,664.26. Following the completion of the transaction, the insider now owns 8,667,207 shares in the company, valued at $5,460,340.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Robert W. Duggan sold 2,354,007 shares of Achaogen stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $0.60, for a total transaction of $1,412,404.20. Following the completion of the transaction, the insider now owns 8,667,207 shares of the company’s stock, valued at approximately $5,200,324.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,431,887 shares of company stock valued at $2,589,886. Company insiders own 7.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc grew its holdings in shares of Achaogen by 8.4% in the third quarter. Vanguard Group Inc now owns 1,675,848 shares of the biopharmaceutical company’s stock valued at $6,687,000 after purchasing an additional 129,804 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Achaogen during the 3rd quarter worth approximately $399,000. Paloma Partners Management Co purchased a new stake in shares of Achaogen during the 3rd quarter worth approximately $174,000. Foresite Capital Management III LLC lifted its position in shares of Achaogen by 20.6% during the 4th quarter. Foresite Capital Management III LLC now owns 2,864,664 shares of the biopharmaceutical company’s stock worth $3,524,000 after buying an additional 490,246 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Achaogen by 2,745.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock worth $1,176,000 after buying an additional 284,407 shares during the last quarter. Hedge funds and other institutional investors own 32.11% of the company’s stock.

WARNING: “Achaogen (AKAO) Hits New 52-Week Low at $0.16” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2019/04/15/achaogen-akao-hits-new-52-week-low-at-0-16.html.

Achaogen Company Profile (NASDAQ:AKAO)

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Featured Story: What is a front-end load?

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.